Anti-Human OX40L (Oxelumab) – Dylight® 488

Anti-Human OX40L (Oxelumab) – Dylight® 488

Product No.: LT1311

- -
- -
Product No.LT1311
Clone
R4930
Target
TNFSF4
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
TNFSF4; GP34; CD252; TXGP1; CD134L; TNLG2B
Isotype
Human IgG1κ
Applications
FA
,
FC

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Expression Host
HEK-293 Cells
FC Effector Activity
Active
Immunogen
Original antibody raised against Human OX40L
Product Concentration
0.2 mg/ml
Formulation
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
Next Day 2-8°C
Excitation Laser
Blue Laser (493 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Oxelumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Additional Applications Reported In Literature ?
FA
Additional Reported Applications For Relevant Conjugates ?
B
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Oxelumab. Clone R4930 binds to Human OX40L (TNFSF4). This product is for research use only.
Background
Oxelumab is a human monoclonal antibody designed for the treatment of autoimmune diseases.3 Oxelumab recognizes human OX40L (TNFSF4). OX40L is a member of the tumor necrosis family and is the ligand for OX40 . The OX40/OX40L interaction generates an optimal T cell response and plays a significant role in determining the amount of memory T-cells remaining after the immune response.1 Therapeutic treatments with antibodies against TNFSF can sometimes result in serious side effects.2 More research is needed to understand the precise molecular mechanism of TNF inhibition. This cost-effective, research-grade Anti-Human OX40L (Oxelumab) utilizes the same variable regions from the therapeutic antibody Oxelumab making it ideal for research projects.
Antigen Distribution
OX40L is expressed in various cell types including antigen presenting cells, T-cells, vascular endothelial cells, mast cells, and natural killer cells.

Antigen Details

PubMed
NCBI Gene Bank ID
Research Area
Costimulatory Molecules
.
Immuno-Oncology
.
Immunology

References & Citations

1. Mahmood,T. and Yang, P. (2012) N Am J Med Sci. 4(11): 533–536
2. Spicer, P. and Runkel, L. (2019) Expert Opin Investig Drugs. 28(2):99-106
3. Heo, YS. et al. (2014) Bio Design 2(2):55-61
FA
Flow Cytometry

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.